Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 5/20 | 0.70 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.70 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.70 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.70 |
| ▸ | LMNA | P02545 | 1/20 | 0.70 |
| ▸ | PGR | P06401 | 1/20 | 0.70 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.70 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.70 |
| ▸ | MAPT | P10636 | 1/20 | 0.70 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.70 |
| ▸ | HPGD | P15428 | 1/20 | 0.70 |
| ▸ | CBR1 | P16152 | 1/20 | 0.70 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.70 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.70 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.60 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.60 |
| ▸ | AR | P10275 | 1/20 | 0.52 |
| ▸ | MRGPRX4 | Q96LA9 | 3/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14861480 | 0.89 | TTR (0.54) | TTRSLC6A3SLC6A2NR1I2LMNA | |
| SCHEMBL14861293 | 0.86 | TTR (0.58) | TTRSLC6A3SLC6A2NR1I2LMNA | |
| Triclosan SCHEMBL28609471 | 0.85 | TTR (0.96) | TTRSLC6A3SLC6A2NR1I2LMNA | |
| Triclosan SCHEMBL29356111 | 0.83 | TTR (1.00) | TTRSLC6A3SLC6A2NR1I2LMNA | |
| Triclosan SCHEMBL29354475 | 0.83 | TTR (1.00) | TTRSLC6A3SLC6A2NR1I2LMNA | |
| Triclosan SCHEMBL3269 | 0.83 | TTR (1.00) | TTRSLC6A3SLC6A2NR1I2LMNA | |
| Triclosan SCHEMBL526378 | 0.83 | TTR (1.00) | TTRSLC6A3SLC6A2NR1I2LMNA | |
| Triclosan SCHEMBL29367506 | 0.83 | TTR (1.00) | TTRSLC6A3SLC6A2NR1I2LMNA | |
| SCHEMBL20554635 | 0.83 | TBXA2R (0.50) | TTRSLC6A3SLC6A2NR1I2LMNA | |
| Triclosan SCHEMBL8975439 | 0.81 | TTR (0.96) | TTRSLC6A3SLC6A2NR1I2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7705047-B2 | Amidoacetonitrile derivatives | NOVARTIS AG (CH) | 2010-04-27 | — | — | US | disclosed |
| EP-1706373-B8 | AMIDOACETONITRILE DERIVATIVES | NOVARTIS AG (CH) | 2010-01-06 | — | — | EP | disclosed |
| EP-1706373-B1 | AMIDOACETONITRILE DERIVATIVES | NOVARTIS AG (CH) | 2009-11-18 | — | — | EP | disclosed |
| US-20070037881-A1 | N-[1-cyano-1-methyl-2-(5-cyano-2-{2,4-dichlorophenoxy}-phenoxy)-ethyl]-4-trifluoromethoxybenzamide; etherification with a cyano-halobenzene in the presence of a basic catalyst; parasiticides, especially antihelmintics; veterinary medicine | ELANCO TIERGESUNDHEIT AG (CH) | 2007-02-15 | — | — | US | disclosed |
| EP-1706373-A1 | AMIDOACETONITRILE DERIVATIVES | Novartis AG (CH) | 2006-10-04 | — | — | EP | disclosed |
| WO-2005058802-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2005-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037881-A1 | N-[1-cyano-1-methyl-2-(5-cyano-2-{2,4-dichlorophenoxy}-phenoxy)-ethyl]-4-trifluoromethoxybenzamide; etherification with a cyano-halobenzene in the presence of a basic catalyst; parasiticides, especially antihelmintics; veterinary medicine | CMA1, H1-2, H1-0 | TTR 2833/4885SLC6A3 3589/4885SLC6A2 985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.